Cargando…

Emerging Role of PD-1/PD-L1 Inhibitors in Chronic Liver Diseases

Programmed cell death protein 1 (PD-1)/PD-ligand (L)1, the immune checkpoint inhibitors have emerged as a promising strategy for the treatment of various diseases including chronic liver diseases (CLDs) such as hepatitis, liver injury and hepatocellular carcinoma (HCC). The role of PD-1/PD-L1 has be...

Descripción completa

Detalles Bibliográficos
Autores principales:	Singh, Vishakha, Khurana, Amit, Allawadhi, Prince, Banothu, Anil Kumar, Bharani, Kala Kumar, Weiskirchen, Ralf
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8733625/ https://www.ncbi.nlm.nih.gov/pubmed/35002724 http://dx.doi.org/10.3389/fphar.2021.790963

Ejemplares similares

Critical neurological features of COVID-19: Role of imaging methods and biosensors for effective diagnosis
por: Singh, Vishakha, et al.
Publicado: (2021)

Role of nanotechnology behind the success of mRNA vaccines for COVID-19
por: Khurana, Amit, et al.
Publicado: (2021)

Can bilirubin nanomedicine become a hope for the management of COVID-19?
por: Khurana, Isha, et al.
Publicado: (2021)

Antimicrobial and anti-viral effects of selenium nanoparticles and selenoprotein based strategies: COVID-19 and beyond
por: Khurana, Amit, et al.
Publicado: (2023)

Silver nanoparticle based multifunctional approach for combating COVID-19
por: Allawadhi, Prince, et al.
Publicado: (2021)

Potential of electric stimulation for the management of COVID-19
por: Allawadhi, Prince, et al.
Publicado: (2020)

Decorin as a possible strategy for the amelioration of COVID-19
por: Allawadhi, Prince, et al.
Publicado: (2021)

It’s all about the spaces between cells: role of extracellular matrix in liver fibrosis
por: Khurana, Amit, et al.
Publicado: (2021)

PD-1/PD-L1 Inhibitors in Cervical Cancer
por: Liu, Yuncong, et al.
Publicado: (2019)

Nanoceria as a possible agent for the management of COVID-19
por: Allawadhi, Prince, et al.
Publicado: (2020)

Allium sativum derived carbon dots as a potential theranostic agent to combat the COVID-19 crisis
por: Kalkal, Ashish, et al.
Publicado: (2021)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
por: Liu, Jinhua, et al.
Publicado: (2021)

PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases
por: Zhang, Ke, et al.
Publicado: (2022)

Value assessment of PD-1/PD-L1 inhibitors in the treatment of oesophageal and gastrointestinal cancers
por: Ou, Shun-Long, et al.
Publicado: (2023)

Editorial: Targeting the PD-1/PD-L1 Cancer Immune Evasion Axis: Challenges and Emerging Strategies
por: Wang, Yiting, et al.
Publicado: (2020)

PD-1/PD-L1 Inhibitor-Associated Myocarditis: Epidemiology, Characteristics, Diagnosis, Treatment, and Potential Mechanism
por: Dong, Hao, et al.
Publicado: (2022)

Results from a Meta-analysis of Combination of PD-1/PD-L1 and CTLA-4 Inhibitors in Malignant Cancer Patients: Does PD-L1 Matter?
por: Feng, Yuqian, et al.
Publicado: (2021)

Editorial: Toxicity Mechanism and Clinical Features of PD-1/PD-L1 Inhibitors in Treatment of Cancer, Volume I
por: Kong, Xiangyi, et al.
Publicado: (2022)

Editorial: Toxicity mechanism and clinical features of PD-1/PD-l1 inhibitors in treatment of cancer, volume II
por: Lei, Chuqi, et al.
Publicado: (2023)

Global trends in the health economics field of PD-1/PD-L1 inhibitors: A bibliometric and visualized study
por: Lai, Sicen, et al.
Publicado: (2023)

Editorial: Targeting the PD-1/PD-L1 cancer immune evasion axis: Challenges and emerging strategies, Volume II
por: He, Xiujing, et al.
Publicado: (2022)

The Prognostic Value of Gastric Immune Prognostic Index in Gastric Cancer Patients Treated With PD-1/PD-L1 Inhibitors
por: Chen, Li, et al.
Publicado: (2022)

PD-1 Inhibitors in the Advanced Esophageal Cancer
por: Hong, Ye, et al.
Publicado: (2019)

The Relative Risk of Immune-Related Liver Dysfunction of PD-1/PD-L1 Inhibitors Versus Chemotherapy in Solid Tumors: A Meta-Analysis of Randomized Controlled Trials
por: Deng, Siyao, et al.
Publicado: (2019)

PD-1/PD-L1 Based Combinational Cancer Therapy: Icing on the Cake
por: Zhang, Jian-ye, et al.
Publicado: (2020)

Safety and Efficacy of Anti-PD-1/PD-L1 Inhibitors Compared With Docetaxel for NSCLC: A Systematic Review and Meta-Analysis
por: Ma, Long, et al.
Publicado: (2021)

Controlling Nutritional Status (CONUT) Predicts Survival in Gastric Cancer Patients With Immune Checkpoint Inhibitor (PD-1/PD-L1) Outcomes
por: Chen, Li, et al.
Publicado: (2022)

Efficacy and safety of PD-1 and PD-L1 inhibitors combined with chemotherapy in randomized clinical trials among triple-negative breast cancer
por: Qi, Yihang, et al.
Publicado: (2022)

Pulmonary adverse events associated with hypertension in non-small cell lung cancer patients receiving PD-1/PD-L1 inhibitors
por: Chen, Jianing, et al.
Publicado: (2022)

Efficacy of PD-1/PD-L1 inhibitors in patients with advanced gastroesophageal cancer: An updated meta-analysis based on randomized controlled trials
por: Gu, Lihu, et al.
Publicado: (2022)

The correlation between the costs and clinical benefits of PD-1/PD-L1 inhibitors in malignant tumors: An evaluation based on ASCO and ESMO frameworks
por: Lin, Shen, et al.
Publicado: (2023)

Corrigendum: Controlling nutritional status (CONUT) predicts survival in gastric cancer patients with immune checkpoint inhibitor (PD-1/PD-L1) outcomes
por: Chen, Li, et al.
Publicado: (2022)

Efficacy and safety of PD-1/PD-L1 inhibitors in the treatment of recurrent and refractory ovarian cancer: A systematic review and a meta-analysis
por: Zeng, Siyuan, et al.
Publicado: (2023)

Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion
por: Wang, Yiting, et al.
Publicado: (2018)

Adverse events of PD-(L)1 inhibitors plus anti-VEGF(R) agents compared with PD-(L)1 inhibitors alone for cancer patients: a systematic review and meta-analysis
por: Tang, Qiyu, et al.
Publicado: (2023)

The influence of pharmaceutical care in patients with advanced non-small-cell lung cancer receiving combination cytotoxic chemotherapy and PD-1/PD-L1 inhibitors
por: Kou, Wen, et al.
Publicado: (2022)

PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
por: Alsaab, Hashem O., et al.
Publicado: (2017)

Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?
por: Chocarro de Erauso, Luisa, et al.
Publicado: (2020)

β-Glucan Combined With PD-1/PD-L1 Checkpoint Blockade for Immunotherapy in Patients With Advanced Cancer
por: Wang, Mengjie, et al.
Publicado: (2022)

Efficacy and Safety of Anti-PD-1/ PD-L1 Monotherapy for Metastatic Breast Cancer: Clinical Evidence
por: Qi, Yihang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_p9fj5jitl8vav7k2qnhsva9ah1